Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.38
ANGO's Cash-to-Debt is ranked lower than
79% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ANGO: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
ANGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 4.53 Max: N/A
Current: 0.38
Equity-to-Asset 0.76
ANGO's Equity-to-Asset is ranked higher than
73% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ANGO: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
ANGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.84 Max: 0.94
Current: 0.76
0.06
0.94
Interest Coverage 7.63
ANGO's Interest Coverage is ranked lower than
82% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. ANGO: 7.63 )
Ranked among companies with meaningful Interest Coverage only.
ANGO' s Interest Coverage Range Over the Past 10 Years
Min: 0.3  Med: 12.23 Max: 31.06
Current: 7.63
0.3
31.06
Piotroski F-Score: 5
Altman Z-Score: 2.99
Beneish M-Score: -3.08
WACC vs ROIC
8.83%
-1.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 6.34
ANGO's Operating Margin % is ranked higher than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. ANGO: 6.34 )
Ranked among companies with meaningful Operating Margin % only.
ANGO' s Operating Margin % Range Over the Past 10 Years
Min: -10  Med: 2.4 Max: 9.75
Current: 6.34
-10
9.75
Net Margin % -7.06
ANGO's Net Margin % is ranked lower than
66% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. ANGO: -7.06 )
Ranked among companies with meaningful Net Margin % only.
ANGO' s Net Margin % Range Over the Past 10 Years
Min: -12.32  Med: 0.16 Max: 6.54
Current: -7.06
-12.32
6.54
ROE % -4.79
ANGO's ROE % is ranked lower than
66% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. ANGO: -4.79 )
Ranked among companies with meaningful ROE % only.
ANGO' s ROE % Range Over the Past 10 Years
Min: -8.28  Med: 0.11 Max: 3.22
Current: -4.79
-8.28
3.22
ROA % -3.47
ANGO's ROA % is ranked lower than
63% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. ANGO: -3.47 )
Ranked among companies with meaningful ROA % only.
ANGO' s ROA % Range Over the Past 10 Years
Min: -5.81  Med: 0.07 Max: 2.96
Current: -3.47
-5.81
2.96
ROC (Joel Greenblatt) % 19.30
ANGO's ROC (Joel Greenblatt) % is ranked higher than
58% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. ANGO: 19.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANGO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16.13  Med: 4.83 Max: 35.18
Current: 19.3
-16.13
35.18
3-Year Revenue Growth Rate -0.10
ANGO's 3-Year Revenue Growth Rate is ranked lower than
66% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ANGO: -0.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANGO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.1  Med: 7.9 Max: 25.2
Current: -0.1
-0.1
25.2
3-Year EBITDA Growth Rate -7.80
ANGO's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ANGO: -7.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANGO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.4  Med: 4.9 Max: 31.9
Current: -7.8
-30.4
31.9
3-Year EPS without NRI Growth Rate 242.90
ANGO's 3-Year EPS without NRI Growth Rate is ranked higher than
98% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ANGO: 242.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANGO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: 6.7 Max: 242.9
Current: 242.9
-39.7
242.9
GuruFocus has detected 3 Warning Signs with AngioDynamics Inc $ANGO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANGO's 10-Y Financials

Financials (Next Earnings Date: 2017-07-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ANGO Guru Trades in Q1 2016

Jim Simons 438,500 sh (+20.33%)
Chuck Royce 720,801 sh (+12.48%)
Paul Tudor Jones Sold Out
Mario Gabelli 66,000 sh (-10.81%)
» More
Q2 2016

ANGO Guru Trades in Q2 2016

Joel Greenblatt 14,848 sh (New)
Jim Simons 494,400 sh (+12.75%)
Chuck Royce 752,109 sh (+4.34%)
Mario Gabelli 66,000 sh (unchged)
» More
Q3 2016

ANGO Guru Trades in Q3 2016

Paul Tudor Jones 55,359 sh (New)
Joel Greenblatt 57,378 sh (+286.44%)
Jim Simons 625,846 sh (+26.59%)
Mario Gabelli 66,000 sh (unchged)
Chuck Royce 690,609 sh (-8.18%)
» More
Q4 2016

ANGO Guru Trades in Q4 2016

Joel Greenblatt 61,144 sh (+6.56%)
Chuck Royce 682,548 sh (-1.17%)
Jim Simons 608,646 sh (-2.75%)
Mario Gabelli 60,000 sh (-9.09%)
Paul Tudor Jones 24,974 sh (-54.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ELGX, AMEX:CRHM, NAS:MLAB, OTCPK:AMSJF, OTCPK:GMDTF, NAS:ATRC, NAS:LMAT, OTCPK:NNCSF, NAS:ATRS, NAS:OSUR, NAS:IRTC, NAS:STAA, NAS:LMNX, NAS:PLSE, NAS:ENTL, OTCPK:CLHLF, NAS:UTMD, NAS:CFMS, NAS:ATRI, NAS:DSCI » details
Traded in other countries:UG2.Germany,
Headquarter Location:USA
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.

AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures & sells medical, surgical & diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease & for use in oncology & surgical settings. Its product offerings fall within three product groupings: Peripheral Vascular, Vascular Access & Oncology/Surgery. The Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. Fluid Management product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers & interventional accessories. These devices are utilized together & allow clinicians to aspirate or inject contrast, saline, remove waste & monitor invasive blood pressures throughout the procedure. Venous products focus on the treatment of varicose veins & consist of its VenaCure EVLT laser system & Sotradecol. VenaCure EVLT laser system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Sotradecol (sodium tetradecyl sulfate injection) is an FDA approved sclerosing drug that it distribute through a agreement with the manufacturer. Thrombus Management product offerings includes AngioVac & thrombolytic products. In fiscal 2013, the Company released its AngioVac venous drainage system which includes a Venous Drainage Cannula & Cardiopulmonary Bypass Circuit. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, & reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins & surgical bypass grafts. The Company's other core peripheral vascular products include Angiographic products & accessories, drainage, micro access & other products. Angiographic products & accessories are used during peripheral vascular interventional procedures. Drainage products percutaneously drain abscesses & other fluid pockets. An abscess is a tender inflamed mass that typically must be drained by a physician. Image-guided vascular access, or IGVA, involves the use of imaging equipment to guide the placement of catheters that deliver short-term drug therapies, such as chemotherapeutic agents & antibiotics, into the central venous system. The BioFlo products incorporate Endexo Technology into the manufacturing & design of its Vascular Access products. A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, & until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. Ports are implantable devices utilized

Top Ranked Articles about AngioDynamics Inc

AngioDynamics to Present at the 41st Annual Deutsche Bank Health Care Conference
AngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders
AngioDynamics Announces Secondary Offering of 2.35 Million Shares of Common Stock by Selling Stockholders
AngioDynamics To Host Investor Day on Thursday, April 6, 2017, in New York City
ALBANY, N.Y., March 27, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, will host an Investor Day on April 6, 2017 in New York City, beginning at 8:45am EDT.
AngioDynamics’ leadership team, including Jim Clemmer, President and Chief Executive Officer; Michael Greiner, Executive Vice President and Chief Financial Officer; and the general managers of each of the Company’s three global franchises, will share the long-term growth strategy and insights into the plan to deliver shareholder value through fiscal year 2020.A live webcast and presentation materials will be available on the investor relations section of the Company's website under "Events & Presentations" at investors.angiodynamics.com/events. A replay and transcript of the webcast will be available shortly after the event.Institutional investors and analysts who wish to attend the Investor Day in-person can contact AngioDynamics via telephone at 1-518-795-1418 or email at [email protected].About AngioDynamicsAngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at AngioDynamics.com.TrademarksAngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Company Contact:
AngioDynamics Inc.
Caitlin Stefanik
(518) 795-1418
[email protected]

Investor Relations Contacts:
FTI Consulting
Jim Polson
(312) 553-6730
[email protected],
Kotaro Yoshida
(212) 850-5690
[email protected]

Media Contact:
FTI Consulting
Kimberly Ha
(212) 850-5612
[email protected]

Read more...
AngioDynamics to Report Fiscal 2017 Third Quarter Financial Results
ALBANY, N.Y., March 20, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 third quarter ended February 28, 2017, on Thursday, March 30, 2017, before the open of the U.S. financial markets.
Management will host a conference call beginning at 8:00am E.T. on March 30 to discuss the results and answer questions. To participate in the live call by telephone, please call 888-299-7212 and reference the Conference ID: 6053267.A live webcast and subsequent archived replay of the conference call may be accessed via the investor relations section of the Company's website under "Events & Presentations" at investors.angiodynamics.com/events. To listen to the live webcast, please go to the website 15-minutes prior to its start to register, download and install the necessary audio software.About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at AngioDynamics.com.Trademarks
AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
Company Contact:
AngioDynamics Inc.
Caitlin Stefanik
(518) 795-1418
[email protected]

Investor Relations Contacts:
FTI Consulting
Jim Polson
(312) 553-6730
[email protected],
Kotaro Yoshida
(212) 850-5690
[email protected]

Media Contact:
FTI Consulting
Kimberly Ha
(212) 850-5612
[email protected]

Read more...
AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System

ALBANY, N.Y., March 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced it has received CE Mark certification for the Solero Microwave Tissue Ablation (MTA) System. The Solero MTA System and Accessories are indicated for the ablation of soft tissue during open, laparoscopic or percutaneous procedures. The Solero MTA System is not intended for cardiac use.
“The Solero Microwave Tissue Ablation System is a significant addition to our portfolio of oncology/surgery products and allows physicians to maximize the volume of tissue ablated in the shortest period of time,” said Rick Stark, Senior Vice President and General Manager of the Oncology/Surgery division of AngioDynamics. “Solero is a single applicator system able to complete up to a 5 cm ablation in 6 minutes at maximum power.” The Solero MTA System features the Solero Microwave (MW) Generator and the specially designed Solero MW Applicators. The solid state Solero MW Generator with a 2.45 GHz operating frequency can power up to 140 W for optimized power delivery and fast ablations. The Solero MW Applicator’s optimized ceramic tip diffuses MW energy nearly spherically, and its patented cooling channel with thermocouple provides real-time monitoring to help protect non-targeted tissue ablation. In addition, the Solero MTA System offers physicians scalability with a single applicator designed for multiple, predictable ablation volumes by varying time and wattage.  About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com. Trademarks
AngioDynamics, the AngioDynamics logo, Solero, and the Solero logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly report on Form 10-Q for the fiscal period ended August 31, 2015 and November 30, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Company Contact:
AngioDynamics Inc.
Caitlin Stefanik
(518) 795-1418
[email protected]

Investor Relations Contacts:
FTI Consulting
Jim Polson
(312) 553-6730
[email protected],
Kotaro Yoshida
(212) 850-5690
[email protected]

Media Contact:
FTI Consulting
Kimberly Ha
(212) 850-5612
[email protected]

Read more...
AngioDynamics to Present at the Barclays Global Healthcare Conference

ALBANY, N.Y., March 08, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer, President and Chief Executive Officer, is scheduled to participate in a Q&A session at the Barclays Global Healthcare Conference on Thursday, March 16, 2017, at 9:00 a.m. ET. The conference will be held at the Loews Miami Beach Hotel in Miami, Fla.
A live audio and/or webcast and subsequent archived replay of AngioDynamics’ session may be accessed via the investor relations section of the Company’s website under “Events & Presentations” at http://investors.angiodynamics.com/events.cfm. The replay will be available for 90 days after the event. About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com. Trademarks
AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
Company Contact:
AngioDynamics Inc.
Caitlin Stefanik
(518) 795-1418
[email protected]

Investor Relations Contacts:
FTI Consulting
Jim Polson
(312) 553-6730
[email protected],
Kotaro Yoshida
(212) 850-5690
[email protected]

Media Contact:
FTI Consulting
Kimberly Ha
(212) 850-5612
[email protected]



Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 23.47
ANGO's Forward PE Ratio is ranked higher than
50% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. ANGO: 23.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 11.37
ANGO's Price-to-Owner-Earnings is ranked higher than
87% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. ANGO: 11.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ANGO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.64  Med: 23.83 Max: 437.5
Current: 11.37
0.64
437.5
PB Ratio 1.08
ANGO's PB Ratio is ranked higher than
86% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. ANGO: 1.08 )
Ranked among companies with meaningful PB Ratio only.
ANGO' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 0.97 Max: 3.69
Current: 1.08
0.64
3.69
PS Ratio 1.61
ANGO's PS Ratio is ranked higher than
69% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ANGO: 1.61 )
Ranked among companies with meaningful PS Ratio only.
ANGO' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.67 Max: 4.88
Current: 1.61
1.02
4.88
Price-to-Free-Cash-Flow 11.76
ANGO's Price-to-Free-Cash-Flow is ranked higher than
84% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. ANGO: 11.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ANGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.78  Med: 25.32 Max: 837.6
Current: 11.76
8.78
837.6
Price-to-Operating-Cash-Flow 10.49
ANGO's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. ANGO: 10.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANGO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.4  Med: 15.12 Max: 252.67
Current: 10.49
8.4
252.67
EV-to-EBIT 32.28
ANGO's EV-to-EBIT is ranked lower than
83% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. ANGO: 32.28 )
Ranked among companies with meaningful EV-to-EBIT only.
ANGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -253.2  Med: 17.2 Max: 4806.5
Current: 32.28
-253.2
4806.5
EV-to-EBITDA 15.03
ANGO's EV-to-EBITDA is ranked higher than
60% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. ANGO: 15.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -874.8  Med: 14.7 Max: 171.6
Current: 15.03
-874.8
171.6
Shiller PE Ratio 134.63
ANGO's Shiller PE Ratio is ranked lower than
100% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. ANGO: 134.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANGO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 41.92  Med: 77.81 Max: 144.58
Current: 134.63
41.92
144.58
Current Ratio 2.86
ANGO's Current Ratio is ranked higher than
61% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ANGO: 2.86 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s Current Ratio Range Over the Past 10 Years
Min: 1.95  Med: 4.65 Max: 14.28
Current: 2.86
1.95
14.28
Quick Ratio 1.73
ANGO's Quick Ratio is ranked higher than
55% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. ANGO: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s Quick Ratio Range Over the Past 10 Years
Min: 1.16  Med: 3.58 Max: 12.12
Current: 1.73
1.16
12.12
Days Inventory 118.63
ANGO's Days Inventory is ranked higher than
53% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. ANGO: 118.63 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s Days Inventory Range Over the Past 10 Years
Min: 116.22  Med: 132.71 Max: 174.24
Current: 118.63
116.22
174.24
Days Sales Outstanding 47.45
ANGO's Days Sales Outstanding is ranked higher than
71% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. ANGO: 47.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.92  Med: 56.47 Max: 79.92
Current: 47.45
45.92
79.92
Days Payable 31.01
ANGO's Days Payable is ranked lower than
80% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. ANGO: 31.01 )
Ranked among companies with meaningful Days Payable only.
ANGO' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 51.69 Max: 110.32
Current: 31.01
31.01
110.32

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
ANGO's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. ANGO: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29  Med: -12.3 Max: -1
Current: -1.1
-29
-1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 28.18
ANGO's Price-to-Tangible-Book is ranked lower than
97% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. ANGO: 28.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANGO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.58  Med: 3.26 Max: 263.11
Current: 28.18
1.58
263.11
Price-to-Intrinsic-Value-Projected-FCF 0.92
ANGO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. ANGO: 0.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ANGO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.2  Med: 0.86 Max: 1.09
Current: 0.92
0.2
1.09
Price-to-Median-PS-Value 0.98
ANGO's Price-to-Median-PS-Value is ranked higher than
57% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ANGO: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANGO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.02 Max: 3.13
Current: 0.98
0.67
3.13
Earnings Yield (Greenblatt) % 3.09
ANGO's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. ANGO: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANGO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 4.7 Max: 12.3
Current: 3.09
0.4
12.3
Forward Rate of Return (Yacktman) % 19.29
ANGO's Forward Rate of Return (Yacktman) % is ranked higher than
56% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. ANGO: 19.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ANGO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: 1.5 Max: 19.4
Current: 19.29
-15.5
19.4

More Statistics

Revenue (TTM) (Mil) $356.1
EPS (TTM) $ -0.71
Beta0.79
Short Percentage of Float4.53%
52-Week Range $11.52 - 18.18
Shares Outstanding (Mil)36.79

Analyst Estimate

May17 May18 May19
Revenue (Mil $) 353 359 368
EPS ($) 0.68 0.66 0.72
EPS without NRI ($) 0.68 0.66 0.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
AngioDynamics to Present at the 41st Annual Deutsche Bank Health Care Conference Apr 20 2017 
AngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders Apr 06 2017 
AngioDynamics Announces Secondary Offering of 2.35 Million Shares of Common Stock by Selling Stockho Apr 06 2017 
AngioDynamics To Host Investor Day on Thursday, April 6, 2017, in New York City Mar 27 2017 
AngioDynamics to Report Fiscal 2017 Third Quarter Financial Results Mar 20 2017 
AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System Mar 14 2017 
AngioDynamics to Present at the Barclays Global Healthcare Conference Mar 08 2017 
Strong Investor Participation and Presentations at Long Island Capital Alliance Healthcare Capital F Feb 16 2016 
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 

More From Other Websites
AngioDynamics to Present at the 41st Annual Deutsche Bank Health Care Conference Apr 20 2017
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering Apr 10 2017
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : April 10,... Apr 10 2017
Endo international, AngioDynamics Lead Biotech Movers Apr 07 2017
AngioDynamics Announces Pricing of Secondary Offering by Selling Stockholders Apr 06 2017
AngioDynamics Announces Secondary Offering of 2.35 Million Shares of Common Stock by Selling... Apr 06 2017
ETFs with exposure to AngioDynamics, Inc. : April 5, 2017 Apr 05 2017
5 Cheap Value Stocks to Tame a Capricious Market in Q2 Apr 04 2017
AngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q3, 2017 By the Numbers : April 4, 2017 Apr 04 2017
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View Mar 31 2017
Edited Transcript of ANGO earnings conference call or presentation 30-Mar-17 12:00pm GMT Mar 30 2017
AngioDynamics tops 3Q profit forecasts Mar 30 2017
AngioDynamics Reports Fiscal 2017 Third Quarter Results Mar 30 2017
Here's Why You Should Steer Clear of Mednax (MD) for Now Mar 29 2017
AngioDynamics To Host Investor Day on Thursday, April 6, 2017, in New York City Mar 27 2017
AngioDynamics to Report Fiscal 2017 Third Quarter Financial Results Mar 20 2017
AngioDynamics Microwave Tissue Ablation System Now CE Marked Mar 15 2017
AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System Mar 14 2017
AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : March 13,... Mar 13 2017
AngioDynamics to Present at the Barclays Global Healthcare Conference Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)